新型低剂量三联单片复方制剂初始治疗高血压的疗效与安全性
这项国际随机双盲安慰剂对照试验纳入295例未用药或仅用1种降压药的成人高血压患者,比较GMRx2四分之一剂量、二分之一剂量与安慰剂的疗效和安全性。结果显示两种剂量均较安慰剂显著降低家庭收缩压,且耐受性良好,提示低剂量三联单片复方可用于高血压初始治疗。
要点
- GMRx2四分之一剂量较安慰剂降低家庭收缩压7.3 mmHg,二分之一剂量降低8.2 mmHg。
- 第4周诊室血压达标率安慰剂37%、四分之一剂量65%、二分之一剂量70%。
- 两种剂量耐受性良好,因不良事件停药率低,无严重电解质异常。
核心结论
- 在轻中度血压升高的成人中,两种剂量的新型低剂量三联单片复方制剂均耐受良好,且较安慰剂有临床相关的降压效果。
研究设计与样本
- 国际、随机、双盲、安慰剂对照、平行组试验,纳入接受0至1种降压药的成人高血压患者,经过2周安慰剂洗脱后,家庭收缩压130至154 mmHg者按2:2:1随机分配。
- 共295例参与者随机,平均年龄51岁,56%为女性,96%完成试验。
主要发现
- 第4周家庭收缩压较安慰剂校正的最小二乘均值差异:GMRx2四分之一剂量-7.3 mmHg(95%CI:-4.5至-10.2),二分之一剂量-8.2 mmHg(95%CI:-5.2至-11.3)。
- 诊室血压降幅分别为8.0/4.0 mmHg和9.5/4.9 mmHg。
- 第4周诊室血压控制(<140/90 mmHg)率:安慰剂37%、四分之一剂量65%、二分之一剂量70%(两剂量与安慰剂比较P<0.001)。
- 因不良事件停药:安慰剂1例(1.6%)、四分之一剂量0例、二分之一剂量6例(5.1%)。
- 血钠或血钾超出正常范围:安慰剂4例(6.3%)、四分之一剂量12例(10.6%)、二分之一剂量12例(10.1%),但无血钠<130或>150 mmol/L、血钾<3.0或>6.0 mmol/L者。
关键数值与推荐
- GMRx2四分之一剂量:替米沙坦10 mg/氨氯地平1.25 mg/吲达帕胺0.625 mg。
- GMRx2二分之一剂量:替米沙坦20 mg/氨氯地平2.5 mg/吲达帕胺1.25 mg。
- 主要疗效终点为随机化至第4周家庭收缩压变化差异,主要安全终点为因不良事件导致的治疗中断。
临床怎么用
- 对于未用药或仅用1种降压药的轻中度高血压成人,可考虑使用低剂量三联单片复方制剂作为初始或早期治疗。
- 四分之一剂量和半剂量均显示有临床意义的降压效果,可根据血压水平选择剂量。
局限性
- 样本量295例,随访至第4周,长期疗效和安全性未评估。
- 研究人群为轻中度血压升高,结果不能外推至重度高血压或已使用多种降压药者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-pill combinations of 3 or more low-dose blood pressure (BP)-lowering drugs hold promise for initial or early treatment of hypertension. OBJECTIVES: The authors conducted a placebo-controlled trial of a new single-pill combination containing low doses of telmisartan, amlodipine, and indapamide in 2 dose options to assess efficacy and safety. METHODS: This international, randomized, double-blind, placebo-controlled, parallel-group trial enrolled adults with hypertension receiving 0 to 1 BP-lowering drugs. After a 2-week placebo run-in during which any BP-lowering medication was stopped, participants were eligible if home systolic BP (SBP) was 130 to 154 mm Hg. Participants were randomized in a 2:2:1 ratio to GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg), GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg), or placebo. The primary efficacy outcome was difference in change in home SBP from randomization to week 4, and primary safety outcome was treatment discontinuation due to an adverse event. RESULTS: From June 14, 2021 to October 18, 2023, a total of 295 participants (mean age: 51 years; 56% female) were randomized and 96% completed the trial. Baseline mean home BP was 139/86 mm Hg and clinic BP was 138/86 mm Hg after placebo run-in. The placebo-corrected least square mean differences in home SBP at Week 4 were -7.3 mm Hg (95% CI: -4.5 to -10.2) for GMRx2 ¼ dose and -8.2 mm Hg (95% CI: -5.2 to -11.3) for GMRx2 ½ dose; reductions for clinic BP were 8.0/4.0 and 9.5/4.9 mm Hg. At Week 4, clinic BP control (<140/90 mm Hg) was 37%, 65%, and 70% for placebo, GMRx2 ¼ dose, and GMRx2 ½ dose, respectively (both doses P < 0.001 vs placebo). Placebo, GMRx2-triple ¼, and GMRx2 ½ treatment discontinuation due to an adverse event occurred in 1 (1.6%), 0, and 6 (5.1%), respectively; out of normal range serum sodium or potassium was observed in 4 (6.3%), 12 (10.6%), and 12 (10.1%), respectively, but no participant had a serum sodium <130/>150 mmol/L or potassium <3.0/>6.0 mmol/L. Serious adverse events were reported by 2 participants in the placebo and GMRx2 ½ groups and none in the GMRx2 ¼ group. CONCLUSIONS: In a population with mild-to-moderate BP elevation, both dose versions of the novel low-dose triple single-pill combination showed good tolerability and clinically relevant BP reductions compared with placebo. (Efficacy and Safety of GRMx2 Compared to Placebo for the Treatment of Hypertension: NCT04518306).
引用
- Rodgers A, Salam A, Schutte AE, et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. J Am Coll Cardiol. 2024. PMID: 39217570. doi:10.1016/j.jacc.2024.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。